SumatriptanBMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6943.1573d (Published 11 June 1994) Cite this as: BMJ 1994;308:1573
- H Kaube,
- A May,
- H C Diener,
- V Pfaffenrath
- Department of Neurology, University of Essen, 45122 Essen, Germany Neurological Practice, 80802 Munich, Germany.
EDITOR, - According to extensive clinical trials, sumatriptan combines high efficacy with good tolerability and safety in acute attacks of migraine.1 Although it has not shown any addictive properties in short term and long term safety studies, we report on seven patients with a longstanding history of migraine in whom misuse of sumatriptan developed. One similar case has been reported recently.2
The seven patients (five women, two men) were aged 47-65 (average 54) and attending specialist headache clinics. Two had migraine …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial